1.Liu, L., et al., Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. Front Pharmacol, 2022. 13: p. 924197.
2.Dostert, C., et al., The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. Physiological Reviews, 2019. 99(1): p. 115-160.
3. Collette, Y., Gilles, A., Pontarotti, P., and Olive, D., A Co-evolution Perspective of the TNFSF and TNFRSF Families in the Immune System. Trends Immunol, 2003. 24 (7), 387–394.
4.Glenney, G.W. and G.D. Wiens, Early Diversification of the TNF Superfamily in Teleosts: Genomic Characterization and Expression Analysis. The Journal of Immunology, 2007. 178(12): p. 7955-7973.
5.Wiens, G.D. and G.W. Glenney, Origin and evolution of TNF and TNF receptor superfamilies. Developmental & Comparative Immunology, 2011. 35(12): p. 1324-1335.
6.Watts, T.H., TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES. Annual Review of Immunology, 2005. 23(1): p. 23-68.
7.Nguyen, J., et al., Quantitative contributions of TNF receptor superfamily members to CD8+ T-cell responses. Molecular Systems Biology, 2021. 17(11): p. e10560.
8.Banner, D.W., et al., Crystal structure of the soluble human 55 kd TNF receptor-human TNFβcomplex: Implications for TNF receptor activation. Cell, 1993. 73(3): p. 431-445.
9.Locksley, R.M., N. Killeen, and M.J. Lenardo, The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology. Cell, 2001. 104(4): p. 487-501.
10.Compaan, D.M. and S.G. Hymowitz, The Crystal Structure of the Costimulatory OX40-OX40L Complex. Structure, 2006. 14(8): p. 1321-1330.
11. Wajant, H., Principles of antibody-mediated TNF receptor activation. Cell Death & Differentiation, 2015. 22(11): p. 1727-1741.
12.Croft, M., C.A. Benedict, and C.F. Ware, Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery, 2013. 12(2): p. 147-168.
13.Assal, A., et al., Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy, 2015. 7(11): p. 1169-1186.
14.Burugu, S., A.R. Dancsok, and T.O. Nielsen, Emerging targets in cancer immunotherapy. Seminars in Cancer Biology, 2018. 52: p. 39-52.
15.Lee, D.H., Update of early phase clinical trials in cancer immunotherapy. BMB Rep, 2021. 54(1): p. 70-88.
16.Segal, N.H., et al., Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res, 2017. 23(8): p. 1929-1936.
17.Sznol, M., et al., Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). Journal of Clinical Oncology, 2008. 26(15_suppl): p. 3007-3007.
18.Post, T.A., SITC 2016: Phase I/II Data Combining Urelumab With Nivolumab Suggest Increased Antitumor Effect in Patients With Melanoma. 2016.
19.Segal, N.H., et al., Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clin Cancer Res, 2018. 24(8): p. 1816-1823.
20.Tolcher, A.W., et al., Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res, 2017. 23(18): p. 5349-5357.
21.Inc., A., Annual Report. Agenus Inc., 2021. https://investor.agenusbio.com/static-files/2f3ed22a-bd00-4e12-a78c-205169623f82.
22.Tolcher, A.W., et al., Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 2021. 39(15_suppl): p. 2634-2634.
23.release, C.n., Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017. Alligator, 2021.
24.Ullenhag, G.J., et al., A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies. Journal of Clinical Oncology, 2021. 39(15_suppl): p. 2646-2646.
27.Zhang, L., Identification of a predictive biomarker and two pharmacodynamic biomarkers to ADG106 treatment, a novel anti-CD137 agonist antibody, in phase I clinical trials. Journal of Clinical Oncology, 2021. 39(15_suppl): p. e14505-e14505.
29.1025MO - First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours. ESMO, 2020.
32.Garralda, E., et al., 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 2020. 8(Suppl 3): p. A250-A251.
34. I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022. Corporate updates, 2022. https://www.i-mabbiopharma.com/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-months-ended-june-30-2022/.
35.Sarina Piha-Paul, M., Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies AACR, 2021.
36.Sarina Piha-Paul1, J.B., Anthony Tolcher3, Sara Hurvitz4, , et al., A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies. ESMO, 2020.
38.Grilley-Olson, J.E., et al., SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors. Journal of Clinical Oncology, 2018. 36(15_suppl): p. 3093-3093.
39.Bajor, D.L., et al., Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology, 2022. 40(4_suppl): p. 559-559.
40.Vonderheide, R.H., et al., Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol, 2007. 25(7): p. 876-83.
41.Vonderheide, R.H. and M.J. Glennie, Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res, 2013. 19(5): p. 1035-43.
42.Beatty, G.L., et al., A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res, 2013. 19(22): p. 6286-95.
43.Nowak, A.K., et al., A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol, 2015. 26(12): p. 2483-90.
44.ajor, D.L., et al., Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology, 2018. 7(10): p. e1468956.
45.Barlesi, F., et al., 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 2020. 8(Suppl 3): p. A178-A178.
46.Calvo, E., et al., A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 2019. 37(15_suppl): p. 2527-2527.
48.Weiss, S., et al., 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Journal for ImmunoTherapy of Cancer, 2021. 9(Suppl 2): p. A422-A422.
49.Kluger, H., et al., Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Research, 2019. 79(13_Supplement): p. CT089-CT089.
50.Padrón, L.J., et al., Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine, 2022. 28(6): p. 1167-1177.
51.Sanborn, R., et al., 405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3). Journal for ImmunoTherapy of Cancer, 2020. 8(Suppl 3): p. A246-A246.
53.Coward, J., et al., Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors. Journal of Clinical Oncology, 2021. 39(15_suppl): p. 2580-2580.
54.Biocytogen/Eucure Biopharma's YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration. Company release, 2021. https://www.eucure.com/en/detail/450.html.